A Study to Investigate the Effect of Roxadustat versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients with Anemia of Chronic Kidney Disease (CKD)

Trial Identifier: D5741C00002
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04655027
Start Date: February 2021
Primary Completion Date: October 2021
Study Completion Date: October 2021

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese (Simplified) Version

Trial Locations

Country Location
China Baotou, China, 14010
China Beijing, China, 100029
China Beijing, China, 100730
China Beijing, China, 100044
China GUANGZHOU, China, 510180
China Jinan, China, 250012
China Shenyang, China, 110001
China Wuhan, China, 430022